Compound with kinase inhibitory activity and preparation method and use thereof
The present invention provides a compound as shown in general formulas (I) or (II) and a pharmaceutically acceptable salt, an isomer or a mixture form thereof, a solvate, a polymorph, a stable isotope derivative, or a prodrug of the same. The compound of the present invention has CDK kinase inhibitory activity and can be used in treating a disease related to CDK kinase, such as a cancer.
1. A compound represented by general formula (I-2), a pharmaceutically acceptable salt thereof, a stereoisomer thereof or a mixture of the stereoisomers, a solvate thereof, or a stable isotope derivative thereof;
wherein,
R 5 is hydrogen;
R 6 is hydroxyl;
m is 1;
Y 1 is CH;
Y 2 is NCH 2 CH 3 .
2. The compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof or a mixture of the stereoisomers, the solvate thereof, or the stable isotope derivative thereof as defined in claim 1 , wherein the compound is
3. A process for preparing the compound represented by the general formula (I-2) as defined in claim 1 , comprising the following steps:
coupling the compound of the general formula (I-A) with the compound represented by the general formula (I-B) under basic and catalyst conditions to obtain the compound represented by the general formula (I-2);
wherein X is halogen; the definitions of R 5 , R 6 , Y 1 , Y 2 , and m are defined as in claim 1 .
4. A pharmaceutical composition comprising a therapeutically effective amount of the compound, the pharmaceutically acceptable salt thereof, the stereoisomer thereof or a mixture of the stereoisomers, the solvate thereof, or the stable isotope derivative thereof as defined in claim 1 , and a pharmaceutically acceptable carrier, diluent or excipient.